Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRP-A218 + itraconazole is a drug combination used in clinical pharmacology studies to evaluate the impact of CYP3A4 inhibition on the pharmacokinetics of KRP-A218. KRP-A218 (also known as HAR-1234) is a novel, orally active small molecule developed by Kyorin Pharmaceutical that acts as an ATP-competitive and subtype-specific inhibitor of phosphatidylinositol 4-kinase beta (PI4KB). By targeting this host cell factor, KRP-A218 inhibits the replication of RNA viruses such as human rhinovirus (HRV) and enteroviruses (EV). Itraconazole, a potent antifungal agent, is utilized in this combination as a strong CYP3A4 inhibitor to assess potential drug-drug interactions during Phase I clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KRP-A218 + itraconazole.